When you hear about promising new antifungal medicines such as Olorofim or Fosmanogepix, you may wonder why the first studies always seem to involve people with invasive aspergillosis — not those with chronic pulmonary aspergillosis (CPA) or allergic bronchopulmonary aspergillosis (ABPA).
It might seem unfair, especially when chronic forms of aspergillosis are so common and long-lasting.
But there are good reasons why research has to begin with invasive disease.
Here’s how it works — and why it’s still good news for everyone living with aspergillosis.
⚠️ 1. Invasive Aspergillosis Is the Most Dangerous Form
Invasive aspergillosis happens when Aspergillus spreads deep into the lungs or bloodstream, usually in people with a very weak immune system — for example, after chemotherapy, transplant, or high-dose steroid use.
Without prompt treatment, it can be fatal within days or weeks.
Because it is so serious, regulators such as the MHRA (UK), EMA (Europe) and FDA (USA) allow new drugs for invasive infections to be tested and reviewed much faster than they would for less urgent diseases.
This approach means that if a new antifungal proves helpful and safe, it can reach patients in greatest need more quickly — often saving lives while also building the data needed for later studies in other conditions.
📈 2. It’s Easier to Measure Whether the Drug Works
For invasive disease, the goal is very clear:
The infection either clears up, or it doesn’t.
That makes the results of a study straightforward to interpret.
With chronic or allergic aspergillosis, improvement takes much longer to measure:
-
Scans may take months to show change,
-
Symptoms can fluctuate naturally, and
-
Other lung problems (like COPD or bronchiectasis) can confuse the results.
So trials in chronic disease need larger patient numbers and longer follow-up, which are expensive and take years. Starting with invasive aspergillosis lets researchers get the essential safety and efficacy answers first.
🧾 3. The Regulatory Framework Focuses on Invasive Disease
Drug-approval rules for antifungals were originally designed for the most life-threatening infections.
Official guidance documents — from the EMA, FDA and others — describe exactly how to test new drugs for invasive fungal infections, but there are no formal international standards yet for chronic or allergic aspergillosis.
That means developers start where the rules are clear — and then adapt once regulators, researchers, and clinicians agree on what a “successful outcome” looks like for chronic disease.
⚖️ 4. Safety and Ethics Come First
When a new antifungal is in early testing, doctors don’t yet know all its side-effects or how it behaves during long-term use.
For ethical reasons, it’s safer to begin in patients with very few other treatment options, where the potential benefit outweighs the risk.
As safety data builds up — including how the medicine interacts with other drugs — it becomes safer to test in people with more stable chronic conditions such as CPA.
🩺 5. Once Proven Safe, Use Can Expand
Once a drug like Olorofim or Fosmanogepix:
-
works well in invasive aspergillosis,
-
has solid safety data, and
-
earns its first licence,
the manufacturer and research partners (such as the National Aspergillosis Centre) can propose new studies in CPA or other forms of aspergillosis.
By then, regulators already know the drug’s risk profile, dosing, and monitoring needs — so further approvals for chronic disease can move faster.
🧩 In Summary
| Reason | Why invasive aspergillosis comes first |
|---|---|
| Urgency | It’s the most life-threatening form, so ethics allow faster testing |
| Clear results | Success or failure can be measured more easily |
| Existing standards | Regulatory guidance already written for invasive disease |
| Safety first | Starts with people who have no other treatment |
| Builds the base | Data from invasive disease supports later CPA/ABPA trials |
🌱 Looking Ahead
Starting with invasive aspergillosis is a gateway, not a dead-end.
Every study adds vital knowledge about how these new antifungals work, how safe they are, and which patients might benefit most.
Once enough evidence exists, clinical trials can — and almost certainly will — expand to include chronic pulmonary aspergillosis (CPA) and possibly even allergic forms of the disease.
So while the research focus may begin with the most critical cases, the progress made there ultimately helps everyone living with aspergillosis.
Latest News posts
News archive